Good morning, traders and degenerates—here’s your wake-up jolt for the day:
Market Pulse Small-cap biotech buzz rips through trading floors this morning after a flurry of FDA and M&A updates lit a fuse under the sector.
Key Movers Sarepta confirms FDA approval of updated Elevidys prescribing information (Thefly.com) and Rollins Capital explores alternatives to the Sotherly Hotels merger deal (Thefly.com)—plus Waldencast’s trademark sale in Japan and refinancing bolstered its balance sheet (GlobeNewswire).
Macro & Politics Neither Wall Street nor Ottawa have the monopoly on market moves—Fennec Pharmaceuticals quietly kicked off a private share offering in Canada (GlobeNewswire), while Japan’s trademark transactions underscore global financing without government bailouts.
What’s Next Watch capacity constraints in data centers for the AI crowd—they’ll spark the next land-play or power-grid squeeze.
Market Commentary
The real story nobody’s shouting about is the data-center bottleneck detailed in “Amazingly, AI companies are still short of data centers — but not money to build them” (SiliconANGLE News). These hyperscalers have capital to burn but are strangled by power hookups, land availability and permit delays—when those walls hit, landlords and grid operators will rake in revenue like never before.
Look at Teamshares going public via SPAC with Live Oak (Biztoc.com) alongside Femasys’ $12 million financing to advance its final FemBloc trial (GlobeNewswire)—one side’s floating blank checks, the other’s leaning on regulation to unlock value. Pairing SPAC sponsors hunting deals with biotechs courting FDA green lights feels like tossing a match into gasoline.
If you want to position for the next squeeze, target land plays or power-grid specialists ahead of that AI build boom, and keep biotech short-squeeze candidates on watch—there’s nothing like a regulatory catalyst and permit crunch to send small caps through the roof.
📈 Breaking Financial News
Femasys Announces Third Quarter Financial Results for 2025
– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens…
Rollins Capital explores alternatives to Sotherly Hotels merger deal
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Sarepta confirms FDA approval of updated Elevidys prescribing information
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Teamshares To Go Public Via SPAC Merger Deal With Live Oak
Special Purpose Acquisition Company (SPAC) Live Oak Acquisition Corp. V (NASDAQ:LOKV) on Friday disclosed a merger agreement with Teamshares Inc.
A SPAC is a Special Purpose Acquisition Company, also called a “blank check company,” which is a company without …
Waldencast plc strengthens balance sheet position with the announcement of a trademark sale for Japan and refinancing of its credit facilities
NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) — Waldencast plc, (NASDAQ: WALD) (“Waldencast” or the “Company”), a global multi-brand beauty and wellness platform, today announced that it had sold its rights to the “Obagi” trademark in Japan to Rohto Pharmaceutica…
Alert: The DeFi Token Set to Explode as Markets Recover Major institutions are f
This isn't speculation – this platform's role is so essential to crypto's financial system that its current price defies all logic. Just Released: The DeFi token set for massive gains as markets heat up – only $3!
🔍 Market Analysis & Insights
Amazingly, AI companies are still short of data centers — but not money to build them
Data centers must be the most boring buildings in the world to look at, but it’s hard to keep our eyes off them these days. Anthropic said this week it’s going to spend $50 billion on data centers just in the U.S. Meta just did a $3 billion deal with Nebius —…
Jim Cramer on Gap: “I Know This Stock’s Inching Higher After a Quarter I Felt Was Pretty Good”
The Gap, Inc. (NYSE:GAP) is one of the stocks Jim Cramer mentioned in his latest comments. Cramer showed optimism in the company’s quarter, as he said: “Glum…”
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates
Received FDA Fast Track designation for stenoparib in advanced ovarian cancer Reported landmark median overall survival now exceeding 25 months…
Earnings live: Applied Materials stock falls, Trump brothers' American Bitcoin revenue doubles
The third quarter earnings season has been mostly positive, with most of the reports in the rearview mirror.
Cytokinetics, Incorporated Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – CYTK
Cytokinetics, Incorporated Sued for Securities Law Violations – Contact the DJS Law Group to Discuss Your Rights – CYTK ……
One specific coin aligns perfectly with Trump's regulatory reforms and vision for America's financial dominance in the digital age. The best part? This platform is already processing more transactions than all its competitors combined, yet remarkably remains under most investors' radar. Get the name of the ideal crypto for Trump's presidency for just $3 before his policies drive prices higher.
Get the name of the ideal crypto for Trump's presidency for just $3 before his policies drive prices higher.
💰 Investment Opportunities
Plaque Psoriasis (Psoriasis Vulgaris) Global Clinical Trials Market Review 2025: Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End Point Status
The report identifies key market opportunities in the Plaque Psoriasis clinical trials sector by offering insights into global trial trends, prominent drug developments, and strategic investment locales. It aids in strategy formulation and cost-effective tria…
A closer look at the unapproved peptide injections promoted by influencers and celebrities
Unapproved peptide drugs have become a trendy new approach to building muscle, smoothing wrinkles and trying to live longer
A closer look at the unapproved peptide injections promoted by influencers and celebrities
Unapproved peptide drugs have become a trendy new approach to building muscle, smoothing wrinkles and trying to live longer
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC) (TSX:FRX) (“Fennec” or the “Company”), a specialty pharmaceutical company, today announced that it intends to engage in a non-brokered offering of its co…
The TRUTH About Trump and Musk?
If you think there's something strange about the “feud” between Trump and Musk… You need to see THIS jaw-dropping video… Because it explains what could REALLY be going on behind the scenes… And how it could hand investors a stake in a $12 trillion revolution. Click here now to see the full story.